7OC0 Stock Chart & Stats
€3.28
-€0.10(-2.43%)
At close: 4:00 PM EDT
€3.28
-€0.10(-2.43%)
Day’s Range― - ―
52-Week Range€2.40 - €7.35
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€82.67M
Enterprise Value€200.97M
Total Cash (Recent Filing)€17.76M
Total Debt (Recent Filing)€2.63M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 05, 2026EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.52
Shares Outstanding32,724,285
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€8.63Price Target Upside163.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.81
Revenue Forecast (FY)€865.00K
Bulls Say, Bears Say
Bulls Say
Expanded Reimbursement OpportunityHigher covered testing frequency strengthens the economic case for the company’s kitted transplant assays and expands the addressable market. More reimbursed monitoring occasions can support recurring utilization, improve customer economics, and create a durable pathway for revenue growth after authorization.
FDA Progress And Product ReadinessProgress through the FDA review, additional study data, and an upcoming SIR meeting indicate that the lead product is advancing toward commercialization. Authorization would remove a major market-access barrier and allow the company to convert development work into broader clinical and laboratory demand.
Clinical Differentiation And Customer EngagementFavorable comparative data and engagement across leading transplant centers provide evidence of clinical credibility and market interest. This combination can support adoption by reference laboratories and hospitals, while strengthening the company’s competitive position as it moves toward commercial launch.
Bears Say
Heavy And Rising Cash BurnCash consumption remains substantial relative to the company’s current revenue base, and updated H2 guidance is above the prior run-rate expectation. Persistent burn increases dependence on external financing or rapid revenue growth, limiting flexibility while commercialization efforts continue.
Small, Declining Revenue And Deep LossesThe current operating model has not yet demonstrated sufficient scale or operating leverage. Low and declining revenue, thin gross margin, and deeply negative profitability mean that future growth must accelerate materially before the business can absorb its cost structure and produce sustainable earnings.
Negative Stockholders’ EquityNegative equity reflects the cumulative impact of prior losses and weakens the balance sheet’s financial cushion. Although reported debt is relatively modest, the erosion of equity can constrain financing flexibility and make it harder to fund regulatory, registry, and commercial initiatives internally.
Insight Molecular Diagnostics News
7OC0 FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was €2.40 and its highest was €7.35 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is €82.67M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Nov 05, 2026 which is in 11 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Aug 10, 2026. The company reported -€0.277 earnings per share for the quarter, missing the consensus estimate of -€0.227 by -€0.05.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.21.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,724,285 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -€0.277 in its last earnings report, missing expectations of -€0.227. Following the earnings report the stock price went down -5.392%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in DE:7OC0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.63 (163.08% Upside)
€8.63 (163.08% Upside)
Blogger Sentiment
Bearish
DE:7OC0 Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.91%
12-Months-Change
Fundamentals
Return on Equity
271.76%
Trailing 12-Months
Asset Growth
-41.72%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
7OC0 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a generally positive operational and commercial outlook driven by regulatory progress (SIR meeting and tripled study samples), favorable Medicare coverage expansion (+75% surveillance tests in first 3 years), strong head-to-head clinical data and customer engagement (over half of top-10 transplant centers engaged), and a clear TAM expansion pathway. Offsetting these positives are material near-term financial risks — elevated cash burn ($10M in Q2; expected ~$8M/quarter in H2, up ~33% vs prior guidance), ongoing adjusted EBITDA losses ($7.8M) and schedule uncertainty around FDA authorization that could delay commercialization. Overall, management’s tone is constructive and forward-looking, but execution and timing risks remain important near-term considerations.View all DE:7OC0 earnings summaries7OC0 Stock 12 Month Forecast
Average Price Target
€8.63
▲(163.08% Upside)
Technical Analysis
Atossa Therapeutics
―
MacroGenics
―
Elutia
―
Surrozen
―
Telomir Pharmaceuticals, Inc.
―